We are live on ! Find out more
ASBP

Aspire Biopharma
ASBP

19 hedge funds and large institutions have $17.9M invested in Aspire Biopharma in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

12% more funds holding

Funds holding: 17 → 19 (+2)

0% more ownership

Funds ownership: 0.02% → 0.02% (+0%)

2% less capital invested

Capital invested by funds: $18.2M → $17.9M (-$289K)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
19
Holders Change
+2
Holders Change %
+11.76%
% of All Funds
0.28%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
3
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FTCM
Fir Tree Capital Management
New York
+$382K
2
GCL
Glazer Capital LLC
New York
+$342K
3
TCM
Tuttle Capital Management
Connecticut
+$184K
4
QL
Quarry LP
New York
+$13.2K

Top Sellers

Rank Fund Capital Flow
1
MSU
Mizuho Securities USA
New York
-$376K
2
PC
Periscope Capital
Ontario, Canada
-$289K
3
SCM
Shaolin Capital Management
Florida
-$210K
4
UBS Group
UBS Group
Switzerland
-$650
5
TRCT
Tower Research Capital (TRC)
New York
-$87
Name Holding Trade Value Shares
Change 		Change in
Stake
FTCM
1
Fir Tree Capital Management
New York
$1.97M +$382K +29 +24%
PC
2
Periscope Capital
Ontario, Canada
$1.91M -$289K -22 -13%
AA
3
AQR Arbitrage
Connecticut
$1.64M – – –
AI
4
Arena Investors
New York
$1.64M – – –
Hudson Bay Capital Management
5
Hudson Bay Capital Management
Connecticut
$1.64M – – –
ETH
6
Exos TFP Holdings
New York
$1.63M – – –
LP
7
LMR Partners
United Kingdom
$1.63M – – –
PSAMP
8
P. Schoenfeld Asset Management (PSAM)
New York
$1.45M – – –
FTCM
9
First Trust Capital Management
Illinois
$1.4M – – –
RCM
10
Radcliffe Capital Management
Pennsylvania
$1.11M – – –
SCM
11
Shaolin Capital Management
Florida
$689K -$210K -16 -23%
WCMNY
12
Westchester Capital Management (New York)
New York
$393K – – –
GCL
13
Glazer Capital LLC
New York
$334K +$342K +26 New
TCM
14
Tuttle Capital Management
Connecticut
$185K +$184K +14 New
RCM
15
Robinson Capital Management
Michigan
$114K – – –
TI
16
Tidal Investments
Wisconsin
$114K – – –
QL
17
Quarry LP
New York
$13.1K +$13.2K +1 New
SOA
18
Sea Otter Advisors
Florida
$12.2K – – –
BlackRock
19
BlackRock
New York
$3.27K – – –
EC
20
Elequin Capital
New York
$109 – – –
MSU
21
Mizuho Securities USA
New York
– -$376K -29 Closed
TRCT
22
Tower Research Capital (TRC)
New York
– -$87 – –
UBS Group
23
UBS Group
Switzerland
– -$650 – –

ASBP Hedge Fund Activity: Q4 2023 in Review

19 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q4 2023, worth a combined $17.9M — down 1.6% from $18.2M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ASBP positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Fir Tree Capital Management, adding an estimated $382K. The largest seller was Mizuho Securities USA, exiting entirely with an estimated $376K sold.

  • 19 institutional investors held Aspire Biopharma (ASBP) as of Q4 2023, up from 17 in Q3 2023.
  • Funds reported $17.9M of Aspire Biopharma stock for Q4 2023, down 1.6% quarter-over-quarter.
  • 3 funds opened new Aspire Biopharma positions in Q4 2023 and 1 closed out, a net change of +2 holders.
  • The largest Aspire Biopharma buyer in Q4 2023 was Fir Tree Capital Management, an estimated $382K added.
  • The largest Aspire Biopharma seller in Q4 2023 was Mizuho Securities USA, an estimated $376K sold.

Based on aggregated 13F filings for Q4 2023.